Docetaxel, Irinotecan, Recurrent, Refractory, Bone and Soft Tissue Sarcomas.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Docetaxel (Primary) ; Irinotecan (Primary)
- Indications Alveolar soft part sarcoma; Bone cancer; Chondrosarcoma; Clear cell sarcoma; Ewing's sarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 13 Sep 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 28 Jun 2011 New trial record